Medical/Pharmaceuticals

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B

-- Estimated 1.59 million chronic hepatitis B (CHB) patients in the U.S. -- Interim results of the Phase IIb trial conducted on CHB patients in China showed that in patients with the baseline hepatitis B surface antigen (HBsAg) level ≤ 500 IU/mL, approximately 19% (3/16) of patients in the treatm...

2022-01-17 18:12 5283

HTPE Leads JYSSBIO to Close Series B+ Funding

HANGZHOU, China, Jan. 17, 2022 /PRNewswire/ -- Huatai International Private Equity Fund ("HTPE"), the Greater China focused private equity investment platform under Huatai Securities, is pleased to announce that it led the Series B+ financing ofZhejiang JYSS Bio-Engineering Co., Ltd.  ("JYSSBIO" ...

2022-01-17 17:58 5190

Frost & Sullivan and TERI's Sustainability 4.0 Awards 2021 Honor Companies Embedding Sustainability with Economic Value Creation

At the 12th edition, 23 awards were presented to companies for their exemplary performance in sustainability MUMBAI, India, Jan. 17, 2022 /PRNewswire/ -- The 12th edition of Frost & Sullivan and The Energy and Resources Institute (TERI)'s Sustainability 4.0 Awards took place virtually on Jan. 12...

2022-01-17 17:30 6060

The Philippines Has Approved ReCOV For Phase II/III Cinical Trial

* Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III Clinical Trial * ReCOV induced high levels of neutralizing antibodies against SARS-CoV-2 and Variants of Concern such as Omicron and Delta * Rhecogen , a subsidiary focused on mRNA vaccines of th...

2022-01-17 16:57 3973

Leading E-commerce Logistics and Fulfillment Brand NextSmartShip Partners with B2B Medical E-commerce Giant LyncMed

SHENZHEN, China, Jan. 17, 2022 /PRNewswire/ -- NextSmartShip , a world-leading fulfillment service provider for global e-commerce sellers, signed a strategic partnership agreement with LyncMed, a major global B2B e-commerce platform for medical instruments. Under ...

2022-01-17 15:00 2269

Green Valley Obtains IND Approval from U.S. FDA for Sodium Oligomannate's Global Phase II Clinical Trial in Treating Parkinson's Disease

SHANGHAI, Jan. 17, 2022 /PRNewswire/ -- On January 13, 2022, Green Valley ( Shanghai) Pharmaceuticals Co., Ltd. received the letter from the US Food and Drug Administration (FDA) on the Investigational New Drug (IND) application for the global multi-center phase-II clinical trial of Oligomannate (...

2022-01-17 14:29 1765

MicroPort CRM Receives Approval in Japan for Alizea Bluetooth Pacemaker

CLAMART, France, Jan. 17, 2022 /PRNewswire/ -- MicroPort CRM, a pioneering company in the field of Cardiac Rhythm Management, headquartered inFrance, recently received PMDA Japanese regulation agency approval for its latest range of implantable pacemakers, Alizea. The devices are equipped with Bl...

2022-01-17 12:18 4350

Xinhua Silk Road: BGI Genomics' star COVID-testing mobile lab product exhibited at China Pavilion of Expo 2020 Dubai

BEIJING, Jan. 17, 2022 /PRNewswire/ -- Models of BGI Genomics' Huo-Yan Air Laboratory, a star nucleic acid-testing mobile lab product of the Chinese giant, were displayed at the China Pavilion of Expo 2020 Dubai duringJanuary 11-13. Compared with regular COVID-testing labs, Huo-Yan Air Labs are ...

2022-01-17 10:22 2432

Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA

BEIJING and SHANGHAI and BOSTON, Jan. 16, 2022 /PRNewswire/ -- Jacobio's self-developed global first-in-class drug Aurora A inhibitor  JAB-2485 received IND (Investigational New Drug) from the FDA (Food and Drug Administration) in US. Jacobio plans to initiate a Phase I/IIa clinical trial in pati...

2022-01-17 09:04 1945

CStone announces the clinical data from registrational study of Sugemalimab in stage III non-small cell lung cancer published in The Lancet Oncology

SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the registrational clinical...

2022-01-15 08:35 7091

CStone announces the registrational clinical study results of sugemalimab in stage IV non-small cell lung cancer published in The Lancet Oncology

SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that results of the GEMSTONE-302...

2022-01-15 08:31 6446

French Consul General in Guangzhou led a delegation to visit Biosyngen in China-Singapore Guangzhou Knowledge City

GUANGZHOU, ChinaJan. 15, 2022 /PRNewswire/ -- On the afternoon of January 14th, Mr. Sylvain FOURRIERE, Consul General ofFrance in Guangzhou, and officers from consulates general of 9 countries includingBritain, Canada and Switzerland visited China-Singapore Guangzhou Knowledge City andSingapore -...

2022-01-15 08:00 7169

China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin

TAIZHOU, China, Jan. 14, 2022 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC ) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of...

2022-01-15 03:30 4564

I-Mab Announces Execution of Senior Management Team Share Purchase Plan

* The execution demonstrates senior management team's tremendous confidence in the Company's innovative globally competitive pipeline and long-term growth prospects SHANGHAI and GAITHERSBURG, MD., Jan. 14, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceut...

2022-01-14 21:00 7450

LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant

Results from ongoing testing and monitoring of COVID-19 variants shows the rapid microfluidic test detects Omicron at a comparable sensitivity to other variants LONDON, Jan. 14, 2022 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced tha...

2022-01-14 19:18 3807

Crunchfish Gesture Interaction introduction - Deeply intuitive gestures

STOCKHOLM, Jan. 14, 2022 /PRNewswire/ -- Crunchfish develops AI technology for gesture interaction with exceptional performance, optimized for augmented and virtual reality (AR/VR), automotive and the next generation digital interfaces. An introduction to gesture Interaction was the topic of the ...

2022-01-14 19:17 3386

Everest Medicines Enters into a Global Licensing Agreement to Develop and Commercialize Singapore's Experimental Drug Development Centre's 3CL Protease Inhibitors as Potentially Best-in-Class COVID-19 Oral Antiviral Treatments Worldwide

SHANGHAI, Jan. 14, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), andSingapore's Experimental Drug Development Centre ("EDDC") today announced a global licensing agreement under which Everest will obtain exclusive...

2022-01-14 08:00 6517

Leading E-commerce Logistics and Fulfillment Brand NextSmartShip Partners with B2B Medical E-commerce Giant LyncMed

SHENZHEN, China, Jan. 13, 2022 /PRNewswire/ -- NextSmartShip , a world-leading fulfillment service provider for global e-commerce sellers, signed a strategic partnership agreement with LyncMed, a major global e-commerce platform for medical instruments. Under this...

2022-01-13 22:40 2563

United Imaging Announces Construction of a World-leading Intelligent R&D and Manufacturing Complex with an Investment of More Than USD 490 million

SHANGHAI, Jan. 13, 2022 /PRNewswire/ -- Recently, the construction of United Imaging's brand new Manufacturing and R&D base of operations officially kicked off. With a total investment ofUSD 490 million and a planned footprint of about 420,000 square meters, the company is creating a modern campu...

2022-01-13 17:43 3078

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne

HANGZHOU and SHAOXING, China, Jan. 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC40 for moderate to severe acne. ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme whic...

2022-01-13 17:30 5047
1 ... 609610611612613614615 ... 644

Week's Top Stories